» Articles » PMID: 38778059

IL-33/NF-κB/ST2L/Rab37 Positive-feedback Loop Promotes M2 Macrophage to Limit Chemotherapeutic Efficacy in Lung Cancer

Overview
Journal Cell Death Dis
Date 2024 May 22
PMID 38778059
Authors
Affiliations
Soon will be listed here.
Abstract

IL-33 is a danger signal that binds to its receptor ST2L to promote tumor progression. This study identifies the IL-33/ST2L positive-feedback loop and the trafficking of ST2L membrane presentation in macrophages that contribute to lung tumor progression. Mechanistically, IL-33 induces ST2L upregulation by activating NF-κB, which binds to the promoter region of the ST2L gene. Moreover, Rab37, a small GTPase involved in membrane trafficking, mediates ST2L trafficking to the plasma membrane of M2 macrophages. This IL-33/NF-κB/ST2L/Rab37 axis promotes positive-feedback loops that enhance ST2L expression and membrane trafficking in M2 macrophages. Notably, neutralizing antibodies against IL-33 or ST2L block NF-κB activity, suppress M2 macrophage polarization, and synergistically inhibit tumor growth when combined with cisplatin treatment in vitro/vivo. Clinically, Rab37/ST2L/CD206 tumor-infiltrating M2 macrophages correlate with advanced-stage lung cancer patients with poor response to chemotherapy. These findings unveil a positive-feedback mechanism and provide a basis for IL-33/ST2L-targeting therapy for cancer.

Citing Articles

Metformin Inhibited GSDME to Suppress M2 Macrophage Pyroptosis and Maintain M2 Phenotype to Mitigate Cisplatin-Induced Intestinal Inflammation.

Jiang K, He Q, Wang C, Yang W, Zhou C, Li J Biomedicines. 2024; 12(11).

PMID: 39595093 PMC: 11592070. DOI: 10.3390/biomedicines12112526.


UBE2M forms a positive feedback loop with estrogen receptor to drive breast cancer progression and drug resistance.

Lin X, Sun D, Yang S, Cheng K, Wang X, Meng W Cell Death Dis. 2024; 15(8):590.

PMID: 39138151 PMC: 11322533. DOI: 10.1038/s41419-024-06979-x.


RAB37-mediated autophagy guards ovarian homeostasis and function.

Xu X, Hu M, Ying R, Zou J, Du Z, Lin L Autophagy. 2024; 20(12):2738-2751.

PMID: 39113565 PMC: 11587855. DOI: 10.1080/15548627.2024.2389568.

References
1.
Chang C, Hu M, Hsiao Y, Wang Y . ST2 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1240:83-93. DOI: 10.1007/978-3-030-38315-2_7. View

2.
Gadani S, Walsh J, Smirnov I, Zheng J, Kipnis J . The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron. 2015; 85(4):703-9. DOI: 10.1016/j.neuron.2015.01.013. View

3.
Kakkar R, Lee R . The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7(10):827-40. PMC: 4277436. DOI: 10.1038/nrd2660. View

4.
Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert E . The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513(7519):564-568. PMC: 4339042. DOI: 10.1038/nature13577. View

5.
Jiang W, Lian J, Yue Y, Zhang Y . IL-33/ST2 as a potential target for tumor immunotherapy. Eur J Immunol. 2021; 51(8):1943-1955. DOI: 10.1002/eji.202149175. View